The interview aims to explore newly presented data on mitapivat across thalassemia, PK deficiency, and sickle cell disease, as featured at the 67th ASH Annual Meeting. The discussion will focus on clinical insights from the ENERGIZE-T Phase 3 subgroup results, long-term transfusion-independence data, pediatric PK deficiency findings, and emerging preclinical data on cardiomyopathy protection. The goal is to contextualize the breadth of evidence supporting mitapivat as an activator of pyruvate kinase across multiple rare blood disorders and understand how these data may shape future therapeutic strategies and trial design.